These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18855676)

  • 1. Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment.
    Angelucci E; Malesci A; Danese S
    Curr Med Chem; 2008; 15(24):2527-35. PubMed ID: 18855676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budesonide in the treatment of inflammatory bowel disease.
    Silverman J; Otley A
    Expert Rev Clin Immunol; 2011 Jul; 7(4):419-28. PubMed ID: 21790284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis.
    Salice M; Rizzello F; Calabrese C; Privitera Hrustemovic H; Gionchetti P
    Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):607-613. PubMed ID: 31106602
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral beclomethasone dipropionate: a critical review of its use in the management of ulcerative colitis and Crohn's disease.
    Fascì Spurio F; Aratari A; Margagnoni G; Doddato MT; Chiesara F; Papi C
    Curr Clin Pharmacol; 2012 May; 7(2):131-6. PubMed ID: 22432845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of inflammatory bowel disease with corticosteroids.
    Katz JA
    Gastroenterol Clin North Am; 2004 Jun; 33(2):171-89, vii. PubMed ID: 15177533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral locally active steroids in inflammatory bowel disease.
    Nunes T; Barreiro-de Acosta M; Marin-Jiménez I; Nos P; Sans M
    J Crohns Colitis; 2013 Apr; 7(3):183-91. PubMed ID: 22784947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
    D'Haens GR; Kovács A; Vergauwe P; Nagy F; Molnár T; Bouhnik Y; Weiss W; Brunner H; Lavergne-Slove A; Binelli D; Di Stefano AF; Marteau P
    J Crohns Colitis; 2010 Jun; 4(2):153-60. PubMed ID: 21122499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
    Gareb B; Eissens AC; Kosterink JGW; Frijlink HW
    Eur J Pharm Biopharm; 2016 Jun; 103():32-42. PubMed ID: 27000751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.
    Cross RK
    Inflamm Bowel Dis; 2017 Oct; 23(10):1689-1701. PubMed ID: 28906290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
    Sandborn WJ; Danese S; D'Haens G; Moro L; Jones R; Bagin R; Huang M; David Ballard E; Masure J; Travis S
    Aliment Pharmacol Ther; 2015 Mar; 41(5):409-18. PubMed ID: 25588902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Budesonide-MMX in active ulcerative colitis.
    Gionchetti P; Praticò C; Rizzello F; Calafiore A; Capozzi N; Campieri M; Calabrese C
    Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):215-22. PubMed ID: 24502535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide for induction of remission in Crohn's disease.
    Otley A; Steinhart AH
    Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis.
    Bonovas S; Nikolopoulos GK; Lytras T; Fiorino G; Peyrin-Biroulet L; Danese S
    Br J Clin Pharmacol; 2018 Feb; 84(2):239-251. PubMed ID: 29057539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
    Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of inflammatory bowel disease for the 21st century.
    Robinson M
    Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?
    De Cassan C; Fiorino G; Danese S
    Dig Dis; 2012; 30(4):368-75. PubMed ID: 22796798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX.
    Vestergaard T; Jørgensen SMD; Christensen LA; Julsgaard M
    Scand J Gastroenterol; 2018 Dec; 53(12):1459-1462. PubMed ID: 30612500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.